Morand EF, et al. - Researchers performed this post-hoc analysis, wherein, they intended to validate the Lupus Low Disease Activity State (LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb randomised controlled trial (RCT) (MUSE) and then to utilize LLDAS to discriminate between anifrolumab and placebo. As per the results, a clinically meaningful SLE outcome measure was represented by LLDAS attainment, and anifrolumab was noted to be related to more patients who met LLDAS criteria compared to placebo. LLDAS as an SLE RCT endpoint was supported.